Researchers have uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor patients respond to the targeted therapy imatinib mesylate. Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.
Full article >>
Wednesday, April 29, 2009
Predicting Patient Response To Gleevec In Gastrointestinal Stromal Tumors
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment